BofA Global Research initiates coverage of Iambic Therapeutics with buy rating; price objective $30
IAM•BofA Global Research initiated coverage of Iambic Therapeutics with a buy rating and a $30 price objective.
Related News
Barings BDC files initial beneficial ownership statement for Vice President William Woody Harrison
BBDC•
Regentis Biomaterials signs exclusive distribution agreement with Ami Technologies for Gelrinc in Israel
RGNT•
Nasdaq trade halt: volatility trading pause at 10:14 a.m.
OMH•
US LNG feedgas demand reaches new record
UNG•
NRG Energy in talks with financing partners for data center buildout, announcement targeted by year-end
NRG•